Papers of the Week
Lessons From Fingolimod for PPMS
Old Drug Performs New Trick
The Secrets of Shapeshifting Cells
Welcome to the Multiple Sclerosis Discovery Forum
Recent research suggests new roles for an old biomarker, autoantibodies to myelin oligodendrocyte glycoprotein, or MOG, a protein component of myelin. Among the new findings, these anti-MOG antibodies are particularly important in pediatric demyelinating diseases.
New insights into how myelin-making cells undergo their radical shape changes may pave the way toward new therapeutic agents to repair demyelinated axons and restore function in diseases such as multiple sclerosis.
In what may be the first demonstration of myelin repair in people with multiple sclerosis, an old antihistamine shows modest improvement in the function of chronically demyelinated optic nerves.
A fundamental question for people with MS is: What will happen to me? A new study finds a highly variable disease trajectory in people with moderate and advanced MS. The past doesn't seem to predict the future. It adds up to hope that outcomes can be improved, no matter what stage of disease, says medical student Nathaniel Lizak on his preliminary findings.
MSDF interviews Brian Weinshenker MD of the Mayo Clinic about innovative ways to do clinical trials involving neuromyelitis optica, now considered a separate disease from MS.
Tools that will help investigators conceive and perform experimental work:
The Data Visualization section presents MS-related data in new ways, making it easy for viewers to discover unexpected relationships
Our latest data visualization presents a network map of the connections among 1253 authors of 263 research papers that reported results of clinical trials in progressive forms of multiple sclerosis between January 1983 and September 2015.
- Drug-Development Pipeline consolidates key information about compounds under investigation for therapeutic use
- Tissue Repositories lists features of the world's tissue repositories and brain banks, including rules of engagement and contact information
- Clinical Trials lists sources of information about MS clinical trials
Drug Database Updates:
In results from a real-life observational study in Denmark, natalizumab and fingolimod had very similar effects on clinical disease activity. Other drugs with important additions and changes are alemtuzumab, cladribine, daclizumab, dimethyl fumarate, glatiramer acetate, interferon beta-1a, interferon beta-1b, MIS416, and rituximab. (updated 4/20/16)
Meetings and Events catalogs future and past meetings of interest to the MS-research community
- Funding Opportunities provides information about where to obtain grants
- Jobs offers descriptions of available positions
Member Directory displays profiles of MS-research community members
Bulletin Board allows MSDF members to post notices
Useful Links lists helpful resources elsewhere on the web
To whom it may concern,
From Dan Howitt regarding physical therapy.